BeiGene | Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants

Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants

Beigene Study ID

BGB-DXP593-101

ClinicalTrials.gov ID

NCT04532294

Study Overview

Sex: All

Age: 18 Years / 60 Years

Study Documents

Study Protocol Statistical Analysis Plan

Study Overview

Sex: All

Age: 18 Years / 60 Years

Study Documents

Study Protocol Statistical Analysis Plan